Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Tonix Pharma ( (TNXP) ).
On July 16, 2025, Tonix Pharmaceuticals announced plans to establish a sales force of 70 to 90 representatives for its TNX-102 SL product candidate, contingent upon FDA approval. This strategic move aims to enhance the company’s market position and operational capabilities in the fibromyalgia treatment sector.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s promising pipeline and strategic corporate events contribute positively to its stock score. However, challenges with profitability and valuation due to ongoing investments and negative earnings temper the overall score. Continued growth prospects and positive market momentum provide a balanced outlook.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing and commercializing innovative pharmaceutical products. The company’s primary product candidate is TNX-102 SL, intended for the management of fibromyalgia, with a market focus on addressing unmet medical needs.
Average Trading Volume: 919,163
Technical Sentiment Signal: Sell
Current Market Cap: $314.7M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.